Richard Paulson, Karyopharm CEO

An­a­lysts ques­tion Karyophar­m's PhI­II en­dome­tri­al can­cer da­ta as biotech will charge ahead to FDA

Karyopharm Ther­a­peu­tics tout­ed on Tues­day Phase III da­ta for a can­cer pro­gram it de­scribed as pos­i­tive, but which Wall Street viewed in a more neg­a­tive light.

The biotech re­port­ed topline re­sults for Xpovio’s piv­otal study in en­dome­tri­al can­cer, say­ing the drug re­duced the risk of dis­ease pro­gres­sion or death by 30% com­pared to place­bo. Karyopharm not­ed the pri­ma­ry end­point of me­di­an pro­gres­sion-free sur­vival came in at 5.7 months for the ac­tive arm and 3.8 months in place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.